TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34792542
Drug: OTTO approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTTO approach (6 weeks of no treatment followed by 6 weeks of OTTO)
Study: 32333897
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg every 4 weeks)
Study: 32333897
Drug: Azathioprine (2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2‐3 mg/kg per day)
Study: 33946137
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL hydro-alcoholic extract of Morus nigra leaves, three times a day
Study: 33246911
Drug: Azithromycin (AZM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (AZM), taken thrice-weekly for 18 months
Study: 38191613
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus chemotherapy
Study: 36121652
Drug: Weekly 1.7‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 1.7‐mg semaglutide subcutaneous injections for 3 to 6 months
Study: 36121652
Drug: Weekly 2.4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 2.4‐mg semaglutide subcutaneous injections for 3 to 6 months
Study: 36121652
Drug: Weekly semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly semaglutide treatment
Study: 33711671
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus FOLFIRI (5 mg/kg every 2 weeks)
Study: 33711671
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus FOLFIRI (400 mg/m2 then 250 mg/m2 weekly)
Study: 35224682
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy after BoNT‐A injection
Study: 35730342
Drug: Topical calcipotriol/urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol/urea 20% (Group D)
Study: 616497225
Drug: Bevacizumab targeting
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab targeting therapy
Study: 616497225
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil (Control)
Study: 34028298
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with bandage treatment
Study: 35648242
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 mg)
Study: 34301661
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of prescription charges for 12 months
Study: 32237005
Drug: Behavioral economics-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral economics-based telehealth intervention (up to $50 per month for daily adherence, $2 deduction for missed doses)
Study: 35589854
Drug: Rituximab (anti-CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (anti-CD20 monoclonal antibody)
Study: 34842524
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard care plus social recovery therapy
Study: 32755254
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg and folic acid 0.8 mg
Study: 35153152
Drug: Two sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sterile water injections
Study: 35153152
Drug: Four sterile
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four sterile water injections
Study: 33740276
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS, 125 mg/tab)
Study: 33740276
Drug: CBS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS plus high-dose proton-pump inhibitor (PPI), esomeprazole 40 mg q.i.d. for 3 days
Study: 34887572
Drug: mRNA-1944 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1944 at doses of 0.1, 0.3, and 0.6 mg/kg, administered via intravenous infusion
Study: 32677891
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral refeeding (EOR)
Study: 32677891
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral refeeding (UOR)
Study: 34052414
Drug: Warming eye
Normalized name: warming eye mask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming eye masks generating moist heat at 40 °C for 10 min once daily for 2 weeks
Study: 32534647
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg daily
Study: 33663581
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers
Study: 32152335
Drug: Melinjo seed
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melinjo seed extract (MSE) 300 mg/day
Study: 32152335
Drug: Melinjo seed
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melinjo seed extract (MSE) 500 or 1000 mg/kg/day
Study: 36219518
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of PRP (Group B, right side)
Study: 37058173
Drug: Rituximab-chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-chemotherapy
Study: 36701005
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (2 times weekly, 4 lower body exercises, 3 sets of 6–10 repetitions at 70–85% of 1 repetition maximum)
Study: 35973626
Drug: Local prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local prophylactic antibiotic therapy with vancomycin-loaded calcium sulfate beads
Study: 35973626
Drug: Conventional IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IV prophylactic antibiotic therapy
Study: 33022574
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of moxidectin, oxibendazole, and pyrantel pamoate
Study: 35437881
Drug: Topical oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxygen therapy (TOT) and standard of care (SOC)
Study: 33058393
Drug: Intralesional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional low dose methylprednisolone (40 mg, once per week for 8 weeks)
Study: 32324197
Drug: 0.016 mg
Normalized name: sulfur 0.016 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.016 mg intravitreous bevacizumab
Study: 32324197
Drug: 0.008 mg
Normalized name: trypsin 0.008 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.008 mg intravitreous bevacizumab
Study: 32324197
Drug: 0.004 mg
Normalized name: phenol 0.004 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.004 mg intravitreous bevacizumab
Study: 32324197
Drug: 0.002 mg
Normalized name: niacin 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.002 mg intravitreous bevacizumab
Study: 35944894
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (PnOIT)
Study: 34267006
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (scaling and root planning) in group II (n=20)
Study: 34942090
Drug: Vi-DT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-DT vaccine (groups A-C)
Study: 34942090
Drug: Vi-TT vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-TT vaccine (group D)
Study: 38844862
Drug: Post-treatment observation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment observation
Study: 32524538
Drug: Video game-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video game-based therapy (VGBT) using Nintendo® Wii and leap motion controller (LMC) games
Study: 35700741
Drug: Intravenous glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glibenclamide (glyburide; BIIB093) treatment
Study: 37888913
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg daily)
Study: 35666967
Drug: Informed standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informed standardized patients (expressing knowledge that antibiotics were not required)
Study: 35666967
Drug: Uninformed standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninformed standardized patients (not expressing knowledge that antibiotics were not required)
Study: 37980801
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy
Study: 35187770
Drug: Originator insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator insulin glargine (IGlar [Lantus®])
Study: 35667873
Drug: ONS (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS (oral nutritional supplements) administered twice daily for 7 days prior to surgery
Study: 39495569
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment
Study: 35452022
Drug: Generalized Vestibular
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized Vestibular Rehabilitation Therapy (GVRT)
Study: 35452022
Drug: Individualized Vestibular
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized Vestibular Rehabilitation Therapy (IVRT)
Study: 35881398
Drug: Smartphone app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone app-based education on prescribing intravenous fluids (group 1)
Study: 35674255
Drug: MOWHTO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOWHTO with ADMSC-injection
Study: 32223318
Drug: Rivaroxaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily)
Study: 32223318
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (100 mg daily)
Study: 34019661
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg OPK-88004 daily for 12 weeks
Study: 34019661
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg OPK-88004 daily for 12 weeks
Study: 34019661
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg OPK-88004 daily for 12 weeks
Study: 33821552
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by intensity-modulated radiotherapy (IC-RT)
Study: 33331529
Drug: Weekly working
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly working hours of the physician
Study: 34407339
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma with a high titer of antibodies against SARS-CoV-2
Study: 33909728
Drug: Rough-surface implants
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface implants
Study: 33909728
Drug: Nobel Biocare
Normalized name: Lidocare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nobel Biocare implants
Study: 33909728
Drug: Sweden &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweden & Martina implants
Study: 32444296
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg intramuscular injection)
Study: 36599365
Drug: Individual Shear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Shear Rate Therapy (ISRT)
Study: 32503946
Drug: ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 10 mg/kg
Study: 36529089
Drug: Extended-release calcifediol
Normalized name: calcifediol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release calcifediol (ERC)
Study: 32503365
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management counseling (individual sessions, four sessions, twice a week at 35 and 36 weeks of gestation)
Study: 36098670
Drug: Deutetrabenazine (24,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (24, 48, and 72 mg)
Study: 33039853
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy + Expiratory Flow Acceleration (EFA)
Study: 37913818
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy (ST)
Study: 34843078
Drug: Nalbuphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.1 mg/kg) combined with propofol
Study: 35949399
Drug: C arm
Normalized name: Drive Cast Protec Arm 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: C arm (standard 4-drug combination pending phenotypic results)
Study: 35575454
Drug: Ultrasound-guided suprascapular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided suprascapular nerve blocks with ropivacaine 5 mL 2 mg/mL
Study: 35575454
Drug: Ultrasound-guided injections
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injections of 5 mL sterile saline solution (NaCl 0.9%)
Study: 33185374
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline injection while supine (A group)
Study: 33185374
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline injection in sitting position (B group)
Study: 35881420
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (fosinopril or hydrochlorothiazide alone or combined with a statin)
Study: 33404758
Drug: Milk supplemented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplemented with 107 CFU/mL of Lactobacillus rhamnosus SP1
Study: 33342316
Drug: Ingestion-time hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion-time hypertension trials following minimum guidelines for treatment timing based on internal biological time (morning vs evening) and assessed using ABPM.
Study: 33342316
Drug: ABPM performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABPM performed with validated devices at least hourly throughout two or more consecutive 24 h periods.
Study: 33059620
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of HIV positive not on antiretroviral treatment to HIV negative using def1
Study: 32408868
Drug: Iyengar-based yoga
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iyengar-based yoga intervention (twice weekly group classes and once weekly home practice for 12 weeks)
Study: 35509178
Drug: Gadolinium-based contrast
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium-based contrast agents
Study: 36053298
Drug: Oral OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OXT (24 IU)
Study: 37153702
Drug: Intranasal OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal OXT
Study: 36227461
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment (OMT arm)
Study: 33357480
Drug: Lenalidomide maintenance
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide maintenance (15 mg per day for platelets >100×10^9 cells/L or 10 mg per day for platelets 60-100×10^9 cells/L, days 1-21 every 28 days) for 24 months
Study: 32988822
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion (CI) of cloxacillin (two 75-mg/kg 12-h infusions per day for 3 days)
Study: 32988822
Drug: Intermittent Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Infusion (ItI) of cloxacillin (four 37.5-mg/kg 1-h infusions per day for 3 days)
Study: 35759680
Drug: 6‐days clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐days clotrimazole 2% vaginal cream once‐daily plus 15‐days concomitant acid pH thymol and zinc‐containing cleansing wash (SaugellaActi3) twice‐daily
Study: 35759680
Drug: 6‐days clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐days clotrimazole treatment alone
Study: 34493259
Drug: Family-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based intervention using motivational interviewing and principles of cognitive‐behavioral therapy
Study: 36166727
Drug: Combination nivolumab/ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination nivolumab/ipilimumab (arm A)
Study: 36166727
Drug: Combination nivolumab/ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination nivolumab/ipilimumab (arm D)
Study: 32656799
Drug: Ongoing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing therapy with lenalidomide
Study: 34676600
Drug: Thiamidol (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamidol (applied daily in Dual Serum followed by Day Care SPF30 or Night Care)
Study: 34676600
Drug: Vehicle (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (applied daily in corresponding vehicle formulations)
Study: 33210408
Drug: Curcumagalactomannosides (CGM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumagalactomannosides (CGM) 400 mg once daily
Study: 33210408
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride (GLN) 500 mg and Chondroitin sulphate (CHN) 415 mg, supplied as a single oral dose twice a day
Study: 34102278
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy intervention
Study: 37639820
Drug: mRNA-1273 COVID-19
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 COVID-19 vaccine
Study: 38191268
Drug: Ebastine 20
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 20 mg
Study: 35915733
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine and massage therapy
Study: 33882526
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (single agents or in combination)
Study: 32638504
Drug: MTX (7.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (7.5-20 mg/week)
Study: 34390504
Drug: Low-dose thymoglobulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thymoglobulin (2.5 mg/kg)
Study: 35256000
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and independent exercise with a single therapy session
Study: 35256000
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and supervised exercise with three therapy sessions over 12 weeks
Study: 32586366
Drug: Low-dose UC-MSCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UC-MSCs (3 × 10^6 cells)
Study: 32586366
Drug: High-dose UC-MSCs
Normalized name: UC-MSCs
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UC-MSCs (6 × 10^6 cells)
Study: 34953526
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL)
Study: 32527283
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as the standard treatment)
Study: 34700212
Drug: KarXT (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: KarXT (a fixed combination of xanomeline and trospium chloride)
Study: 33412611
Drug: Selatogrel (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 30 minutes after selatogrel)
Study: 33412611
Drug: Selatogrel (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 30 minutes after selatogrel)
Study: 33412611
Drug: Selatogrel (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 12 hours after selatogrel)
Study: 33412611
Drug: Selatogrel (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 12 hours after selatogrel)
Study: 33412611
Drug: Selatogrel (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selatogrel (16 mg subcutaneous) + Ticagrelor (180 mg, 30 minutes after selatogrel)
Study: 33412611
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Clopidogrel (300 or 600 mg, 30 minutes after placebo)
Study: 33412611
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Prasugrel (60 mg, 30 minutes after placebo)
Study: 33412611
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ticagrelor (180 mg, 30 minutes after placebo)